KCNA5 and atrial fibrillation: The inhibition efficacy of 5,7,4′-trimethylapigenin on hKv1.5 was also confirmed in the human atrial myocytes IKur, which suggests that the Kv1.5 α subunit is the dominant target for the drug (channel blocker) needed in the treatment of atrial fibrillation.